Thyrocare Technologies Limited

Thyrocare Technologies Limited

API Holdings Limited has submitted a disclosure under SEBI Takeover Regulations regarding the amalgamation of Docon Technologies Private Limited with API Holdings Limited, resulting in API acquiring 51.02% of Thyrocare Technologies Limited's paid-up share capital.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has informed the Exchange about Copy of Newspaper Publication pertaining to Notice of transfer of equity shares of the Company to Investor Education and Protection Fund.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has informed the Exchange regarding the approval of the Scheme of Amalgamation of Docon Technologies Private Limited with API Holdings Limited by the Hon'ble National Company Law Tribunal, Mumbai Bench.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has informed the Exchange regarding the complete discharge and release of Transaction Documents pursuant to full redemption and repayment of Non-Convertible Debentures by API Holdings Limited.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has submitted a disclosure under SEBI Takeover Regulations, as per Regulation 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has received a disclosure from Docon Technologies Private Ltd under SEBI Takeover Regulations, submitting a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has received a communication from its promoter, Docon Technologies Private Limited, regarding the release of a pledge on 7,94,69,696 equity shares of the company. The pledge was created to secure the obligations of API Holdings Limited, the holding company, in respect of non-convertible debentures. The debentures have been fully redeemed and repaid, and the pledge has been fully released.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has informed the Exchange regarding communication received from Promoter regarding sale of 1,57,69,696 Equity Shares of the Company by Promoter - Docon Technologies Private Limited. The shares sold represent approximately 9.90% of the total paid-up equity share capital of the Company. Following the aforesaid transaction, Docon continues to be a Promoter and holding company of Thyrocare.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has received a communication from its promoter, Docon Technologies Private Limited, regarding the release of a pledge on 1,75,00,000 equity shares held by Docon. The shares were pledged as security for non-convertible debentures issued by API Holdings Limited, the holding company of Docon. The release of the pledge was done by Catalyst Trusteeship Limited, acting as the debenture trustee, on August 11, 2026.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has informed the Exchange about Earnings Call Transcript held on July 23, 2026. The transcript is available on the company's website and will be uploaded on the Stock Exchange website. The discussion may be forward looking in nature and must be viewed in relation to the risks pertaining to the business.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has resubmitted its unaudited financial results for the quarter ended June 30, 2026, in machine-readable format, as per the National Stock Exchange's circular.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has published unaudited financial results for the quarter ended June 30, 2026, in newspapers and on its website.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has made available the audio recording of its earnings conference call held on July 23, 2026, for its unaudited financial results for the quarter ended June 30, 2026, on its website.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has announced that its Board of Directors has in-principle approved the evaluation of a proposed demerger of its wholly-owned subsidiary Nueclear Healthcare Limited's radiology business undertaking.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has informed the Exchange regarding re-appointment of M/s. Ernst & Young LLP as Internal Auditor of the Company for the Financial Year 2026-27.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has informed the Exchange about Investor Presentation on Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 2026.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a 24% year-on-year growth in consolidated revenue, driven by a 26% increase in the Pathology segment, and a 34% year-on-year growth in EBITDA and PAT.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has announced the outcome of its board meeting, which included the approval of unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the limited review report. The board also approved the re-appointment of Ernst & Young LLP as the internal auditor for the financial year 2026-27.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has informed the Exchange about Schedule of meet for analysts/investors to discuss the Company’s Unaudited Financial Results for the quarter ended June 30, 2026.

Thyrocare Technologies Limited

Thyrocare Technologies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026, confirming that the regulation is not applicable to the company as all shares are in demat form and no rematerialisation requests were received during the quarter.